Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Solasia Pharma KKTSE:4597 +3.85%49 PB Ratio is 4.32 as of Jul. 14, 2026, which is 2% above its 10-year median of 4.24. GuruFocus rates TSE:4597 with a GF Score™ of 49/100 and a GF Value™ of 円2.42 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 921 Drug Manufacturers companies, Solasia Pharma KK ranks worse than 77.74% on this metric.
The historical rank and industry rank for Solasia Pharma KK's PB Ratio or its related term are showing as below:
TSE:4597'
s PB Ratio Range Over the Past 10 Years
Min: 1.7 Med: 4.24 Max: 10.2
Current: 4.32
During the past 13 years, Solasia Pharma KK's highest PB Ratio was 10.20. The lowest was 1.70. And the median was 4.24.
TSE:4597's PB Ratio is ranked worse than 77.74% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.9
vs TSE:4597: 4.32
During the past 12 months, Solasia Pharma KK's average Book Value Per Share Growth Rate was 59.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -27.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -30.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -17.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Solasia Pharma KK was 186.20% per year. The lowest was -37.40% per year. And the median was -26.05% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Solasia Pharma KK PB Ratio Related Terms
Solasia Pharma KK PB Ratio Historical Data
* Premium members only.
The historical data trend for Solasia Pharma KK's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Solasia Pharma KK's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solasia Pharma KK PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Solasia Pharma KK's PB Ratio distribution charts can be found below:
* The bar in red indicates where Solasia Pharma KK's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Solasia Pharma KK (TSE:4597) has a PB Ratio of 4.32 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Solasia Pharma KK and its competitors. This is near median its historical median of 4.24. Over the past decade, Solasia Pharma KK's PB Ratio has ranged from 1.70 to 10.20. According to the industry distribution chart, Solasia Pharma KK ranks #716 out of 921 companies in the Drug Manufacturers industry, placing it in the top 77.7%.
Is Solasia Pharma KK's PB Ratio too high?
Solasia Pharma KK's current PB Ratio of 4.32 is near median its 10-year median of 4.24. Over the past 10 years, this metric has ranged from a low of 1.70 to a high of 10.20. The Drug Manufacturers industry median PB Ratio is 1.90. Solasia Pharma KK's value of 4.32 is 127.4% above this industry median. Based on the distribution chart, Solasia Pharma KK ranks #716 out of 921 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Solasia Pharma KK has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Solasia Pharma KK's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Solasia Pharma KK ranks #716 out of 921 companies for PB Ratio. This places Solasia Pharma KK in the lower half of its industry. The industry median PB Ratio is 1.90. Solasia Pharma KK's value of 4.32 is 127.4% above this benchmark. Historically, Solasia Pharma KK's own PB Ratio has ranged from 1.70 to 10.20 over the past decade. While the company's 10-year median is 4.24 vs. the industry median of 1.90, Solasia Pharma KK has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Solasia Pharma KK's current PB Ratio of 4.32 is 127.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Solasia Pharma KK and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solasia Pharma KK's current PB Ratio is 4.32, which is near median its own 10-year median of 4.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solasia Pharma KK stock overvalued right now?
Based on GuruFocus' analysis, Solasia Pharma KK (TSE:4597) is currently considered Significantly Overvalued. The stock's GF Value™ is 円2.42, compared to a current price of 円27.00 — trading 1015.7% above its estimated fair value. The current PB Ratio is 4.32, which is near median its 10-year median of 4.24 and 127.4% above the Drug Manufacturers industry median of 1.90. Solasia Pharma KK's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Solasia Pharma KK (TSE:4597), the current PB Ratio is 4.32 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Solasia Pharma KK (TSE:4597) Overvalued in 2026?
Based on GuruFocus' analysis, Solasia Pharma KK stock appears to be overvalued.
The current stock price of 円27.00 is trading 1015.7% above its estimated GF Value™ of 円2.42.
GuruFocus considers Solasia Pharma KK to be Significantly Overvalued.
Key valuation signals for TSE:4597:
PB Ratio: 4.32 (near median its 10-year median of 4.24)
GF Value™: 円2.42 vs. price of 円27.00 (1015.7% above fair value)
Industry Position: 127.4% above the Drug Manufacturers median (#716 of 921)
No single metric tells the full story. See the TSE:4597 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4597 has been successfully added to your 
